Funding innovative research on infections
What is antimicrobial resistance?
Antimicrobial resistance, shortened to AMR, is when the bugs that cause infections adapt so that antimicrobial medicines (such as antibiotics) are no longer as effective or stop working as treatments. AMR matters because antimicrobial medicines are an important part of day-to-day treatment for many people with CF.
If an infection develops resistance to one medicine, then a course of a different, stronger treatment is given that may have more unpleasant side effects. For some infections, doctors are running out of alternative medicines to treat them.
To beat AMR, we’re funding research to understand how the bugs work, how we can detect infections more quickly, and better ways to treat them.
-
All about bugs!
To work out how to detect and treat bugs that cause lung infections, we need to know more about them. Trust-funded researchers have found out more about how they move from one person to another, where they like to live, what they eat, how they talk to each other and how they interact with our natural defences that are part of the immune system.
How has our funding moved things on?
The biggest impact so far is that Trust-funded research has led to changes in hospital procedures to reduce the spread of NTM infections from one person with CF to another.
Read more in our 2021 research impact report
What do we still need to know?
We need to understand how different bugs interact with each other. For example, what happens when there are two infection-causing bugs growing in the lungs of someone with CF? New knowledge will help us to diagnose these infections and treat them.
-
Detecting and diagnosing infections
We’ve supported innovative research projects, both in university labs and biotech companies, to look at faster ways of detecting infections and learn more about exacerbations.
How has our funding moved things on?
Over the last 10 years many people in the CF community have been helping researchers find out whether data from wearable health technology can be used to predict an exacerbation, before symptoms appear. The Trust has funded early studies in this area, and we’re delighted to see the support from other funders to progress these ideas further.
Check out the latest updates on this research
What do we still need to know?
Researchers are looking for other samples they can use to detect infections instead of sputum. Examples like dogs sniffing chemicals in people’s socks and collecting exhaled breath in a bag are being considered, as well as more conventional methods such as blood and urine samples! The hope is that this will make it easier to detect signs of infection as early as possible in those that can’t produce sputum. This research is taking place in our Precision-CF Innovation Hub, part of the CF Lung Health Network, funded by LifeArc and Cystic Fibrosis Trust.
-
Researching new treatments
There are many stages of development for a new treatment: the discovery of a potential new treatment approach, the development of the medicine itself, and testing its safety, effectiveness and routes of delivery. We have funded research studies at each of these stages.
How has our funding moved things on?
An important step in developing a new treatment is checking the treatment can get to the right place in the body. For an antibiotic, that means getting medicines inside the bacteria causing the infection.
As parents may relate to, toddlers love throwing their toys out of their cots faster than you can put them back in again. Trying to get antibiotics into bacteria is a bit like this, because bacteria have pumps for removing foreign chemicals that get inside them (including medicines).
Researchers in our first Innovation Hub on lung health worked out ways to design new medicines to prevent this from happening.
Find out more in our Innovation Hub impact report
What do we still need to know?
Researchers are investigating ways to use bacteriophages to treat bacterial infections. Bacteriophages, also known as phages, are naturally occurring viruses that only infect and kill bacteria. It’s still very early days, but the number of CF researchers that are working in this area is exciting. To find out more, read the article on phages in the latest CF Life magazine, or look at the section on phage therapies on our website.
Laura and Sarah share their experiences of living with CF lung infections.
Read more about our research goal to improve the diagnosis and treatment of CF lung infectionsOur research isn't possible without our amazing supporters.
Please consider making a donation today to help power ground-breaking research, drive campaigns to improve standards of care, and support people with CF and their loved ones every step of the way.